New research findings show that an FDA-approved oral immunotherapy for older children and adolescents safely increased peanut protein tolerance in peanut-allergic children aged 1-3 years.
The study suggests this treatment approach may provide a safe and effective means of preventing allergic reactions associated with peanut protein in children younger than age 4.